[1] LI Y, SHI H, WANG W M, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study [J]. Medicine (Baltimore), 2016, 95(24): e3872.
[2] ZUO L, WANG M, HOU F, et al. Anemia Management in the China Dialysis Outcomes and Practice Patterns Study [J]. Blood Purif, 2016, 42(1): 33-43.
[3] VLAGOPOULOS P T, TIGHIOUART H, WEINER D E, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease [J]. J Am Soc Nephrol, 2005, 16(11): 3403-10.
[4] WALKER A M, SCHNEIDER G, YEAW J, et al. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine [J]. J Am Soc Nephrol, 2006, 17(8): 2293-8.
[5] FARAG Y M, KEITHI-REDDY S R, MITTAL B V, et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients [J]. Clin Nephrol, 2011, 75(6): 524-33.
[6] BARANY P, MULLER H J. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease [J]. Nephrol Dial Transplant, 2007, 22 Suppl 4: iv10-iv8.
[7] SINGH A K. Diabetes, anemia and CKD: Why TREAT? [J]. Curr Diab Rep, 2010, 10(4): 291-6.
[8] HUNG S C, KUO K L, PENG C H, et al. Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease [J]. J Am Heart Assoc, 2015, 4(1): e001480.
[9] RAMANATH V, GUPTA D, JAIN J, et al. Anemia and chronic kidney disease: making sense of the recent trials [J]. Reviews on Recent Clinical Trials, 2012, 7(3): 187-96.
[10] ECKARDT K U, SCHERHAG A, MACDOUGALL I C, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD [J]. J Am Soc Nephrol, 2009, 20(12): 2651-60.
[11] SZCZECH L A, BARNHART H X, INRIG J K, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes [J]. Kidney Int, 2008, 74(6): 791-8.
[12] PFEFFER M A, BURDMANN E A, CHEN C Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease [J]. N Engl J Med, 2009, 361(21): 2019-32.
[13] DRUEKE T B, PARFREY P S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s) [J]. Kidney Int, 2012, 82(9): 952-60.
[14] NURKO S. Anemia in chronic kidney disease: causes, diagnosis, treatment [J]. Cleve Clin J Med, 2006, 73(3): 289-97.
[15] LEE K H, HO Y, TARNG D C. Iron Therapy in Chronic Kidney Disease: Days of Future Past [J]. Int J Mol Sci, 2021, 22(3).
[16] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组;. 肾性贫血诊断与治疗中国专家共识(2018修订版) [J]. 中华肾脏病杂志, 2018, 34(11): 860-6.
[17] OOI M, HIBBS S, CHEN F E. The safety of modern intravenous iron infusions in patients with rheumatoid arthritis - a review of the literature [J]. Hematology, 2020, 25(1): 108-11.
[18] GARBOWSKI M W, BANSAL S, PORTER J B, et al. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways [J]. Haematologica, 2020, Online ahead of print.
[19] AUERBACH M, HENRY D, DELOUGHERY T G. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia [J]. Am J Hematol, 2021, 96(6): 727-34.
[20] PARK H, LIU X, HENRY L, et al. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015) [J]. BMC Nephrol, 2018, 19(1): 318.
[21] NISSENSON A R, SWAN S K, LINDBERG J S, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients [J]. Am J Kidney Dis, 2002, 40(1): 110-8.
[22] AKIZAWA T, KOSHIKAWA S, IWASAKI M, et al. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients [J]. Ther Apher Dial, 2007, 11(3): 220-6.
[23] KAPLAN J M, SHARMA N, DIKDAN S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease [J]. Int J Mol Sci, 2018, 19(2).
[24] JOHARAPURKAR A A, PANDYA V B, PATEL V J, et al. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases [J]. J Med Chem, 2018, 61(16): 6964-82.
[25] CHEN N, HAO C, PENG X, et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis [J]. N Engl J Med, 2019, 381(11): 1001-10.
[26] CHEN N, HAO C, LIU B C, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis [J]. N Engl J Med, 2019, 381(11): 1011-22.
[27] AKIZAWA T, OTSUKA T, REUSCH M, et al. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study [J]. Ther Apher Dial, 2020, 24(2): 115-25.
[28] COYNE D W, ROGER S D, SHIN S K, et al. Roxadustat for CKD-related Anemia in Non-dialysis Patients [J]. Kidney Int Rep, 2021, 6(3): 624-35.
[29] PROVENZANO R, SZCZECH L, LEONG R, et al. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials [J]. Clin J Am Soc Nephrol, 2021, 16(8): 1190-200.
[30] TANG M, ZHU C, YAN T, et al. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat [J]. Front Pharmacol, 2021, 12: 658079.
[31] VIGANO S M, FILIPPO S D, MILIA V L, et al. Prospective randomized pilot study on the effects of two synthetic high-flux dialyzers on dialysis patient anemia [J]. Int J Artif Organs, 2012, 35(5): 346-51.
[32] SHEETZ M, BARRINGTON P, CALLIES S, et al. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease [J]. Br J Clin Pharmacol, 2019, 85(5): 935-48.
